[go: up one dir, main page]

AU2002339348A1 - Inhibition of STAT-1 - Google Patents

Inhibition of STAT-1

Info

Publication number
AU2002339348A1
AU2002339348A1 AU2002339348A AU2002339348A AU2002339348A1 AU 2002339348 A1 AU2002339348 A1 AU 2002339348A1 AU 2002339348 A AU2002339348 A AU 2002339348A AU 2002339348 A AU2002339348 A AU 2002339348A AU 2002339348 A1 AU2002339348 A1 AU 2002339348A1
Authority
AU
Australia
Prior art keywords
stat
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002339348A
Other versions
AU2002339348B2 (en
Inventor
Markus Hecker
Andreas H Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avontec GmbH
Original Assignee
Avontec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10148886A external-priority patent/DE10148886A1/en
Application filed by Avontec GmbH filed Critical Avontec GmbH
Publication of AU2002339348A1 publication Critical patent/AU2002339348A1/en
Application granted granted Critical
Publication of AU2002339348B2 publication Critical patent/AU2002339348B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002339348A 2001-10-04 2002-10-02 Inhibition of STAT-1 Ceased AU2002339348B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10148886A DE10148886A1 (en) 2001-10-04 2001-10-04 Inhibition of STAT-1
DE10148886.6 2001-10-04
PCT/DE2002/003748 WO2003030944A2 (en) 2001-10-04 2002-10-02 Inhibition of stat-1

Publications (2)

Publication Number Publication Date
AU2002339348A1 true AU2002339348A1 (en) 2003-07-03
AU2002339348B2 AU2002339348B2 (en) 2007-07-26

Family

ID=7701323

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339348A Ceased AU2002339348B2 (en) 2001-10-04 2002-10-02 Inhibition of STAT-1

Country Status (15)

Country Link
US (2) US7485628B2 (en)
EP (1) EP1432452B1 (en)
JP (1) JP2005508947A (en)
CN (1) CN1630535A (en)
AT (1) ATE290404T1 (en)
AU (1) AU2002339348B2 (en)
CA (1) CA2461064A1 (en)
DE (2) DE10148886A1 (en)
ES (1) ES2239253T3 (en)
IL (1) IL160791A0 (en)
NO (1) NO20041780L (en)
PL (1) PL370413A1 (en)
PT (1) PT1432452E (en)
RU (2) RU2311910C2 (en)
WO (1) WO2003030944A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50214201D1 (en) 2001-06-05 2010-03-25 Curevac Gmbh Stabilized mRNA with increased G / C content, encoding a bacterial antigen and its use
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en) * 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US8361976B2 (en) * 2004-07-09 2013-01-29 University Of Massachusetts Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
DE102004042546A1 (en) * 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
AU2006204120A1 (en) * 2005-01-06 2006-07-13 Benitec, Inc. RNAi agents for maintenance of stem cells
JP2010507361A (en) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn, as an immunostimulant/adjuvant.
DE102006035618A1 (en) * 2006-07-31 2008-02-07 Curevac Gmbh Nucleic acid of the formula (I): GlXmGn, in particular as immunostimulating adjuvant
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
MX2010008468A (en) 2008-01-31 2010-08-30 Curevac Gmbh NUCLEIC ACIDS COMPRISING FORMULA (NuGlX<sub >mGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS.
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010111471A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CN102091333B (en) * 2010-11-23 2012-05-30 中国人民解放军第二军医大学 Application of miR-124 in preparation of anti-septic shock drugs
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2747762T3 (en) 2013-08-21 2020-03-11 Curevac Ag Respiratory syncytial virus (RSV) vaccine
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
CN105920583B (en) * 2016-05-25 2019-05-24 南通大学 The application of 183aa micromolecule polypeptide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976835A (en) * 1992-03-19 1999-11-02 The Rockefeller University Nucleic acids encoding receptor recognition factor Stat1α and Stat1β, and methods of use thereof
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5716622A (en) * 1995-01-06 1998-02-10 The Rockefeller University Functionally active regions of signal transducer and activators of transcription
US5821053A (en) * 1995-02-10 1998-10-13 Center For Blood Research, Inc. LIL-Stat DNA binding sites and methods for identifying inhibitory binding agents
FR2775003A1 (en) 1998-02-19 1999-08-20 Transgene Sa Identifying compounds that inhibit interaction between STAT1 and USF1 peptides, for modulating gene expression, particularly of that encoding class II transactivator
AU5856100A (en) 1999-07-02 2001-01-22 Universitair Medisch Centrum Utrecht Antiviral therapy
EP1362600B1 (en) * 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
DE10148828B4 (en) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation of the expression of STAT-1-dependent genes
US7320694B2 (en) * 2004-03-11 2008-01-22 Coopersurgical, Inc. Obturator tip

Similar Documents

Publication Publication Date Title
AU2002339348A1 (en) Inhibition of STAT-1
AU2002363005A1 (en) Derivatives of uk-2a
AU2002256418A1 (en) Inhibitors of bace
AU2003222197A1 (en) Inhibition of rna function
AU2001266225A1 (en) Decondensation of dna
AU2002219900A1 (en) Minimal identification of features
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002356615A1 (en) Novel utilization of cyclopentabenzofurans
AU2002360394A1 (en) Facilitation of rna interference
AU2002316552A1 (en) Inhibitor of t cell activation
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
AU2002305868A1 (en) Inhibitors of reggamma
EP1238585B8 (en) Use of esterquats
GB0100151D0 (en) Methods of sputtering
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2001286584A1 (en) Inhibition of protein-protein interaction
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2002359898A1 (en) Preparation of alpha-diimines
AU2002246290A1 (en) Superstability of thin-walled structures
AU2002360614A1 (en) Methods of inhibiting fertility
AU2002328906A1 (en) Inhibitors of polyq-aggregation
AU2002321556A1 (en) Inhibition of replication factor c
HU0104370D0 (en) Honeyed schnaps of oerseg
AU2002307475A1 (en) Inhibition of jun kinase
AU2002240837A1 (en) Identification of lead structures